Ozempic vs Retatrutide: Cost and Access Head-to-Head

What Are These Two Drugs and How Do They Differ Mechanistically?

Ozempic and retatrutide both act on the GLP-1 receptor, but that is where the similarity ends. Ozempic is a selective GLP-1 receptor agonist. Retatrutide simultaneously activates GIP, GLP-1, and glucagon receptors, giving it three separate mechanisms to suppress appetite, improve insulin sensitivity, and increase energy expenditure through glucagon-driven thermogenesis.

Ozempic: Selective GLP-1 Agonism

Semaglutide, the active molecule in Ozempic, binds the GLP-1 receptor with high affinity. The FDA approved Ozempic for type 2 diabetes in December 2017 and expanded its label in March 2023 to include cardiovascular risk reduction in adults with T2D and established cardiovascular disease, based on the SUSTAIN-6 trial [1]. The drug is administered once weekly by subcutaneous injection at doses of 0.25 mg (initiation), 0.5 mg, 1.0 mg, or 2.0 mg [2].

GLP-1 receptor activation slows gastric emptying, reduces glucagon secretion, and acts on hypothalamic satiety centers to cut caloric intake [3]. These combined effects produce meaningful HbA1c reductions and moderate weight loss in most patients with T2D.

Retatrutide: The Triple Agonist Approach

Retatrutide (LY3437943, Eli Lilly) adds GIP and glucagon receptor co-agonism to GLP-1 activation. GIP receptor stimulation amplifies insulin secretion and may reduce the nausea burden seen with pure GLP-1 drugs. Glucagon receptor activation increases resting energy expenditure, a mechanism that pure GLP-1 agents do not engage [4].

This triple agonism is the reason retatrutide's Phase 2 weight-loss data look substantially different from semaglutide's T2D trial data. The drug is currently in Phase 3 development. No head-to-head trial against semaglutide has been published.

Efficacy Data: What the Trials Actually Show

Because no published head-to-head trial compares Ozempic directly to retatrutide, the best available evidence comes from each drug's own key trials. Patient populations differ between studies, so direct numeric comparisons carry real limitations.

SUSTAIN-7: Ozempic in Type 2 Diabetes

The SUSTAIN-7 trial (N=1,201) compared semaglutide 0.5 mg and 1.0 mg against dulaglutide 0.75 mg and 1.5 mg over 40 weeks in adults with T2D inadequately controlled on metformin [5]. Semaglutide 1.0 mg produced a mean body-weight reduction of 6.5 kg versus 3.0 kg for dulaglutide 1.5 mg (P<0.001). HbA1c dropped 1.5 percentage points from a baseline of approximately 8.2% with semaglutide 1.0 mg.

SUSTAIN-7 enrolled patients with established T2D, not people seeking obesity treatment alone. Weight loss in the range of 5.5 to 7.3 kg over 40 weeks reflects typical semaglutide performance in a T2D population, where metabolic disease itself limits weight-loss response.

Jastreboff et al. Phase 2 (NEJM 2023): Retatrutide in Obesity

The landmark Phase 2 retatrutide trial (N=338) enrolled adults with a BMI of 27 to 50 kg/m² and at least one weight-related comorbidity but without T2D [6]. Participants received weekly subcutaneous retatrutide at 1 mg, 4 mg, 8 mg, or 12 mg, or placebo for 48 weeks.

At the 12 mg dose, participants achieved a mean body-weight reduction of 24.2% from baseline, compared with 2.1% in the placebo group (P<0.001). The 8 mg arm reached 17.5% mean reduction [6]. Gastrointestinal side effects were the most common adverse events, consistent with GLP-1 class effects, and dose-dependent nausea was noted during uptitration.

The authors noted: "Retatrutide led to a substantial reduction in body weight over 48 weeks in participants with obesity, with dose-dependent efficacy." [6]

Putting the Numbers in Context

A 24.2% mean weight reduction in a non-diabetic obesity trial should not be compared directly to a 5.5 to 7.3 kg reduction in a T2D trial without accounting for population differences, baseline BMI, and trial design. Semaglutide's obesity-specific trial, STEP-1 (N=1,961), produced 14.9% mean weight loss at 68 weeks with semaglutide 2.4 mg (Wegovy formulation, not Ozempic) [7]. Retatrutide's 12 mg Phase 2 result still exceeds that figure by approximately 9 percentage points, which is a clinically meaningful gap if Phase 3 data replicate it.

FDA Approval Status and Regulatory Pathway

The approval gap between these two drugs is the most consequential factor shaping access in 2025.

Ozempic's Regulatory Standing

The FDA approved Ozempic (semaglutide injection) in December 2017 under NDA 209637. The label covers adults with T2D for glycemic control and, since 2023, for reducing the risk of major adverse cardiovascular events [2]. Ozempic is not FDA-approved for chronic weight management; Wegovy (semaglutide 2.4 mg) carries that separate indication. Prescribing Ozempic for obesity in a patient without T2D is legal but off-label [8].

Retatrutide's Investigational Status

As of January 2025, retatrutide has not received FDA approval for any indication. Eli Lilly filed an Investigational New Drug (IND) application and is running Phase 3 trials, including TRIUMPH-1 for obesity [9]. Until the FDA reviews a New Drug Application and grants approval, retatrutide cannot be legally marketed or dispensed by licensed U.S. Pharmacies in its branded form.

Compounding pharmacies, operating under 503A or 503B frameworks, have begun producing retatrutide. The FDA has not placed retatrutide on its list of bulk substances that may be compounded under 503A, which creates a legal gray area for compounded versions [10]. Patients and clinicians should confirm current FDA guidance before pursuing compounded retatrutide.

Cost Comparison: Ozempic vs Retatrutide

Cost is one of the starkest differences between these two drugs right now.

Ozempic Pricing in 2025

Novo Nordisk's U.S. Wholesale acquisition cost (WAC) for Ozempic is approximately $935 per 28-day supply across all doses. Retail cash prices at major pharmacies typically run $900, $1,050 per month. Novo Nordisk offers a savings card capping out-of-pocket costs at $25 per month for eligible commercially insured patients [11]. Uninsured patients without manufacturer assistance commonly pay full list price.

Medicare Part D covers Ozempic for T2D under most formularies, though tier placement varies by plan. The Inflation Reduction Act provisions for Medicare negotiation may affect semaglutide pricing in future contract years, but as of 2025 the WAC listed above applies [12].

Retatrutide Pricing: Not Yet Set

No commercial WAC for retatrutide exists. Eli Lilly has not disclosed launch pricing for any retatrutide product. Analysts tracking GLP-1 market dynamics project pricing in the range of $800, $1,400 per month based on tirzepatide (Mounjaro/Zepbound) precedent and the added manufacturing complexity of triple agonism, but these are estimates only [13].

Compounded retatrutide from 503A pharmacies is currently available at prices ranging from roughly $200, $600 per month, depending on the pharmacy and dose. These products are not FDA-evaluated for safety, identity, potency, or purity.

Out-of-Pocket Cost Summary

| Drug | Monthly List Price | Insurance Coverage | Manufacturer Savings | Compounding Available | |---|---|---|---|---| | Ozempic (semaglutide 0.5 to 2.0 mg) | ~$935, $1,050 | Yes (T2D formulary) | $25/mo cap (eligible) | Yes (gray area post-shortage) | | Retatrutide | Not established | None | None | Yes (legal gray area) |

Insurance Coverage and Access Pathways

Ozempic Insurance Coverage

Most commercial insurance plans covering diabetes medications include Ozempic on formulary. A 2023 analysis found that approximately 85% of commercially insured T2D patients had Ozempic covered at Tier 2 or Tier 3 [14]. Prior authorization is standard, generally requiring documented T2D diagnosis, HbA1c above a threshold (commonly 7.5 to 8.0%), and evidence of metformin use or contraindication.

Medicare Part D plans vary. Most cover Ozempic for T2D but apply step-therapy requirements. Coverage for the cardiovascular risk-reduction indication may depend on whether the plan recognizes that label expansion in its formulary criteria.

Retatrutide Access in 2025

Retatrutide access runs through two channels only: enrolling in an active Phase 3 clinical trial, or obtaining compounded retatrutide from a 503A pharmacy.

Eli Lilly's TRIUMPH-1 and related Phase 3 trials are enrolling at selected academic and clinical research sites. ClinicalTrials.gov (NCT05929261 and related records) lists active sites and eligibility criteria [9]. Trial participation provides retatrutide at no drug cost but requires protocol visits, randomization to placebo arm risk, and adherence to strict exclusion criteria.

Compounded retatrutide occupies uncertain legal territory. The FDA has not authorized retatrutide as a bulk substance for 503A compounding. Patients who choose this route should obtain documentation from the pharmacy on the sourcing of raw material and independent third-party assay results confirming identity and potency.

Telehealth Prescribing Considerations

Ozempic is prescribable via telehealth in all 50 states for T2D. Clinicians operating through telehealth platforms follow the same prescribing standards as in-person physicians: confirmed diagnosis, appropriate workup, and monitoring for adverse effects including pancreatitis and thyroid C-cell tumor risk (as stated in the Ozempic black-box warning) [2].

Prescribing compounded retatrutide via telehealth involves the same regulatory uncertainties described above. The prescribing clinician bears responsibility for informed consent that includes disclosure of the drug's investigational status and the absence of FDA evaluation of the compounded product.

Side Effect Profiles: Where They Overlap and Diverge

Both drugs share GLP-1-mediated side effects. Nausea, vomiting, diarrhea, and constipation are the most common adverse events for each. In SUSTAIN-7, nausea affected approximately 18 to 23% of semaglutide-treated patients [5]. In the retatrutide Phase 2 trial, nausea affected up to 47% of participants in the 12 mg arm during uptitration, though the rate fell with dose stabilization [6].

Side Effects Specific to Retatrutide's Extra Mechanisms

Glucagon receptor agonism can increase heart rate and has hepatic effects not seen with pure GLP-1 agents. The Phase 2 retatrutide data showed a mean increase in heart rate of approximately 5 to 6 beats per minute at higher doses [6]. Long-term cardiovascular implications of sustained glucagon receptor activation are not yet established because no outcomes trial for retatrutide has been completed.

GIP receptor agonism is shared with tirzepatide (Mounjaro), which has a well-characterized safety profile from SURPASS trials [15]. The addition of glucagon agonism in retatrutide is the novel variable that Phase 3 trials are specifically powered to evaluate for safety signals.

Contraindications: Shared and Drug-Specific

Both drugs carry class-level warnings for personal or family history of medullary thyroid carcinoma and Multiple Endocrine Neoplasia syndrome type 2, based on rodent carcinogenicity findings common to GLP-1 receptor agonists [2]. Retatrutide's complete contraindication profile will be established upon NDA review.

Ozempic is contraindicated in pregnancy. Novo Nordisk maintains a pregnancy exposure registry (1-800-727-6500). Women of reproductive potential should use contraception and discontinue Ozempic at least 2 months before planned conception [2].

Who Is Each Drug Most Appropriate For Right Now?

The practical decision between Ozempic and retatrutide today is not primarily a clinical question. It is a regulatory and access question. The clinical picture matters for the longer term.

Ozempic Is the Choice When:

• The patient has confirmed T2D and needs an FDA-approved, insurable GLP-1 agonist.
• The prescribing goal includes cardiovascular risk reduction with an established outcomes trial (SUSTAIN-6, SELECT).
• The patient cannot access clinical trials or does not want compounded investigational drugs.
• The patient needs a drug with a decade of post-market safety data, given semaglutide's approval history dating to 2017.

Retatrutide May Be Considered When:

• The patient has severe obesity (BMI above 40 kg/m²) and inadequate response to semaglutide or tirzepatide.
• The patient qualifies for and is willing to enroll in a Phase 3 trial.
• The patient accepts the investigational status and the legal uncertainty of compounded supply.
• The patient's clinician has access to retatrutide through a research institution or is affiliated with an active TRIUMPH-1 trial site.

A clinician treating a patient with T2D, cardiovascular disease, and BMI of 34 kg/m² should reach for Ozempic or tirzepatide first. These are FDA-approved, carry outcomes data, and are insurable. A research-eligible patient with class III obesity and metabolic dysfunction who has failed two approved GLP-1-based therapies represents a more reasonable candidate for trial enrollment.

Switching From Ozempic to Retatrutide: What Clinicians Need to Know

No published protocol governs switching from semaglutide to retatrutide. Guidance from the American Diabetes Association's 2024 Standards of Care recommends a shared decision-making approach for GLP-1 therapy selection and switching, taking into account efficacy, side effects, cost, and patient preference [16].

Practically, semaglutide has an elimination half-life of approximately 1 week. A washout period of 4 to 5 weeks (approximately five half-lives) would reduce plasma semaglutide to low levels before initiating a new GLP-1-active agent. Given that retatrutide also activates the GLP-1 receptor, overlapping agents could theoretically compound GI side effects without additive glycemic benefit.

A switch from Ozempic to retatrutide also involves moving from an FDA-approved drug with insurance coverage to either a clinical trial protocol or a compounded product without insurance coverage. Patients should understand that insurance will not reimburse compounded retatrutide and that the switch disrupts an established prior authorization record that may be difficult to reinstate if the patient wishes to return to Ozempic.

What Phase 3 Data Will Change This Picture

The TRIUMPH-1 trial (NCT05929261) is evaluating retatrutide at 4 mg, 8 mg, and 12 mg versus placebo in adults with obesity over 52 weeks, with a primary endpoint of percent change in body weight [9]. Eli Lilly has indicated a potential NDA submission in 2025 to 2026 if Phase 3 data replicate Phase 2 results.

If Phase 3 confirms the 24.2% mean weight loss seen in the Phase 2 12 mg arm, retatrutide would represent the most effective approved pharmacotherapy for obesity by a substantial margin. The STEP-1 semaglutide 2.4 mg result of 14.9% [7] and the SURMOUNT-1 tirzepatide 15 mg result of 20.9% [17] would both fall below Phase 2 retatrutide at the top dose.

Regulatory approval would immediately change the cost and access picture. Eli Lilly would establish a commercial WAC, pharmacy benefit managers would negotiate formulary placement, and the compounding gray area would likely close under FDA guidance, as occurred with semaglutide when Novo Nordisk resolved the shortage designation.

The ADA 2024 Standards of Care state: "For patients with type 2 diabetes who have established cardiovascular disease, heart failure, or chronic kidney disease, a GLP-1 receptor agonist or SGLT2 inhibitor with proven cardiovascular or renal benefit is recommended." [16] Retatrutide will need cardiovascular outcomes data to enter that sentence.